Back to results
US 2021/0231647 A1Published application
Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
AssigneeSiemens Healthcare Diagnostics Inc.
InventorsJay J. Li, David J. Ledden, Eric Scott Cowden, Donglai Lu
Life of this patent
Estimating the term…
Abstract
A chemiluminescent detection system, as well as kits and microfluidics devices containing same, are disclosed. Methods of using the system, kits, and devices are also disclosed.
Claims16
A method for detecting the presence and/or concentration of a specific analyte in a sample, comprising the steps of:
- (a) combining, either simultaneously or wholly or partially sequentially:
- (i) a sample suspected of containing the specific analyte;
- (ii) a first composition comprising a singlet-oxygen activatable chemiluminescent compound and a first antibody or binding fragment thereof associated therewith, wherein the first antibody or binding fragment thereof is a detection antibody that specifically binds to a first epitope of a specific analyte;
- (iii) a second composition comprising a singlet-oxygen activatable chemiluminescent compound and a second antibody or binding fragment thereof associated therewith, wherein the second antibody or binding fragment thereof is a detection antibody that specifically binds to a second epitope of the analyte, and wherein the first and second epitopes at least partially overlap such that the first and second antibodies or binding fragments thereof cannot both bind to a single analyte molecule, and wherein the first and second epitopes are not identical;
- (iv) a third composition comprising a third antibody or binding fragment thereof, the third antibody or binding fragment thereof being a capture antibody that specifically binds to a third epitope of the analyte that does not overlap with the first and second epitopes, whereby a single analyte molecule can bind the third antibody or binding fragment thereof and one of the first and second antibodies or binding fragments thereof;
- and
- (v) a sensitizer capable of association with the third antibody or binding fragment thereof, the sensitizer being capable of generating singlet oxygen in its excited state;
- (b) allowing the binding of (ii), (iii) and/or (iv) to analyte within the sample, wherein a first sandwich complex comprising an analyte molecule and (ii) and (iv) is formed, and a second sandwich complex comprising another analyte molecule and (iii) and (iv) is formed, and wherein (v) associates with (iv) in the first and second sandwich complexes, thus bringing the sensitizer into close proximity to the chemiluminescent compounds of (ii) and (iii);
- (c) activating the sensitizer to generate singlet oxygen, wherein activation of the sensitizer present in the first and second sandwich complexes causes the activation of the chemiluminescent compounds present in the first and second sandwich complexes;
- (d) determining the amount of chemiluminescence generated by the activated chemiluminescent compounds present in the first and second sandwich complexes;
- (e) optionally repeating steps (b)-(d);
- and
- (f) detecting the presence and/or concentration of the analyte by analyzing the amount of chemiluminescence so produced, wherein the amount of chemiluminescence is directly proportional to the amount of analyte in the sample.
10 more elements
Dependencies are inferred from the claim text.